Growth Factor Alterations in Advanced Diabetic Retinopathy: A Possible Role of Blood Retina Barrier Breakdown

Chronic hyperglycemia may cause growth factor alterations that are likely to participate in tissue remodeling typical for diabetic late complications. However, few details of such events are known. The ocular vitreous fluid allows studies of growth factor levels in human eyes (after vitrectomy). The vitreous is highly inert and protected by the blood-retina barrier and thus probably reflects growth factor production by the normal retina. Vitreous from patients with proliferative diabetic retinopathy (PDR) was compared with vitreous obtained from patients with nonproliferative eye disease and with vitreous from patients without diabetes but with marked neovascular proliferations due to ischemia. This design permits us to distinguish diabetes-related from non-diabetes-related alterations. Insulin-like growth factor I (IGF-I), IGF-II, IGF binding protein 2 (IGFBP-2), and IGFBP-3 were elevated 3-to 13-fold in nondiabetic retinal ischemia and 1.5- to 3-fold in PDR, indicating that the changes were not restricted to diabetes. These changes may partially be explained by leakage of serum into the vitreous, since IGFs and IGFBPs are 20- to 50-fold higher in serum than in vitreous, and vitreous protein content was 1.5-fold elevated in PDR subjects and 5-fold in ischemia patients compared with control subjects. TGF-β is a proposed antiangiogenic factor in the eye. TGF-β2 was the predominant subtype in vitreous, and its total amount was not altered in PDR patients. More importantly, the active fraction of TGF-β was decreased by 30 and 70% in PDR and nondiabetic retinal ischemia patients, respectively. Since plasmin may control TGF-β activation, the serum protein α2-antiplasmin was measured and found to be significantly elevated to 150 and 250% of control values in PDR and ischemia patients, respectively. Thus, influx of serum proteins due to microvascular disturbances and hypoxia is proposed as a possible cause for vitreous alterations of IGF-I and of active TGF-β. These changes seem to occur late in the sequence of events leading to PDR and are not specific for diabetes, but they were also observed in other diseases characterized by retinal hypoxia.

[1]  K Muraoka,et al.  Midperipheral fundus involvement in diabetic retinopathy. , 1981, Ophthalmology.

[2]  R. Larkins,et al.  Pancreatic islets synthesize phospholipids de novo from glucose via acyl-dihydroxyacetone phosphate. , 1985, Biochemical and biophysical research communications.

[3]  J. Massagué,et al.  Transforming growth factor-beta stimulates the expression of fibronectin and collagen and their incorporation into the extracellular matrix. , 1986, The Journal of biological chemistry.

[4]  D. Greene,et al.  Sorbitol, phosphoinositides, and sodium-potassium-ATPase in the pathogenesis of diabetic complications. , 1987, The New England journal of medicine.

[5]  A. Cerami,et al.  Advanced glycosylation end products in tissue and the biochemical basis of diabetic complications. , 1988, The New England journal of medicine.

[6]  Sandra R. Smith,et al.  An activated form of transforming growth factor beta is produced by cocultures of endothelial cells and pericytes. , 1989, Proceedings of the National Academy of Sciences of the United States of America.

[7]  E. Kohner,et al.  Progression of Diabetic Retinopathy and Changes in Serum Insulin-Like Growth Factor I (IGF I) during Continuous Subcutaneous Insulin Infusion (CSII) , 1989, Hormone and metabolic research = Hormon- und Stoffwechselforschung = Hormones et metabolisme.

[8]  M. Sporn,et al.  Correlation of fibrosis and transforming growth factor-beta type 2 levels in the eye. , 1989, The Journal of clinical investigation.

[9]  R. Farese,et al.  Glucose‐induced synthesis of diacylglycerol de novo is associated with translocation (activation) of protein kinase C in rat adipocytes , 1989, FEBS letters.

[10]  London P. Cuatrecasas.  Peptide Growth Factors and Their Receptors I , 1990, Handbook of Experimental Pharmacology.

[11]  J. McAvoy,et al.  Growth factors in the eye. , 1990, Progress in growth factor research.

[12]  K. Miyazono,et al.  Latent forms of TGF-beta: molecular structure and mechanisms of activation. , 1991, Ciba Foundation symposium.

[13]  M. Sporn,et al.  Transforming growth factor beta isoforms in the adult rat central and peripheral nervous system , 1991, Neuroscience.

[14]  E. de Juan,et al.  Altered distribution of basic fibroblast growth factor in diabetic retinopathy. , 1991, Archives of ophthalmology.

[15]  V. Mukku,et al.  Generation of antibodies and assays for transforming growth factor beta. , 1991, Methods in enzymology.

[16]  Martina,et al.  Receptor-specific induction of insulin-like growth factor I in human monocytes by advanced glycosylation end product-modified proteins. , 1992, The Journal of clinical investigation.

[17]  E. Ruoslahti,et al.  Transforming growth factor-beta in disease: the dark side of tissue repair. , 1992, The Journal of clinical investigation.

[18]  A. Paterson,et al.  Glucose and glucosamine regulate growth factor gene expression in vascular smooth muscle cells. , 1992, Proceedings of the National Academy of Sciences of the United States of America.

[19]  J. Nyengaard,et al.  Hyperglycemic Pseudohypoxia and Diabetic Complications , 1993, Diabetes.

[20]  M. Sporn,et al.  Nerve growth factor induces transcription of transforming growth factor-beta 1 through a specific promoter element in PC12 cells. , 1994, The Journal of biological chemistry.

[21]  T. Lyons,et al.  Platelet Plasminogen Activator Inhibitor 1 in Patients With Type II Diabetes , 1994, Diabetes Care.

[22]  G. Pinna,et al.  Plasma Endothelin in NIDDM Patients With and Without Complications , 1994, Diabetes Care.

[23]  D. Mukhopadhyay,et al.  Hypoxic induction of human vascular endothelial growth factor expression through c-Src activation , 1995, Nature.

[24]  A. Pfeiffer,et al.  Diabetic microvascular complications and growth factors. , 2009, Experimental and clinical endocrinology & diabetes : official journal, German Society of Endocrinology [and] German Diabetes Association.

[25]  H. Hammes,et al.  Subcutaneous injection of a cyclic peptide antagonist of vitronectin receptor–type integrins inhibits retinal neovascularization , 1996, Nature Medicine.